Lumevoq demonstrates sustained improvement of BCVA up to 5 years in LHON

Key takeaways:
BOSTON — Results from the long-term RESTORE study show patients with Leber hereditary optic neuropathy with ND4 mutation who were treated with Lumevoq had sustained improvement of best-corrected visual acuity in both eyes.
Valérie Biousse, MD, professor of neuro-ophthalmology and neurology at Emory Eye Center, also said that patients had quality-of-life improvement up to 5 years after intravitreal injection of Lumevoq (lenadogene nolparvovec, GenSight Biologics), here at the American Academy of Neurology annual meeting.
The RESTORE study included 62 of 72 patients

Key takeaways:
BOSTON — Results from the long-term RESTORE study show patients with Leber hereditary optic neuropathy with ND4 mutation who were treated with Lumevoq had sustained improvement of best-corrected visual acuity in both eyes.
Valérie Biousse, MD, professor of neuro-ophthalmology and neurology at Emory Eye Center, also said that patients had quality-of-life improvement up to 5 years after intravitreal injection of Lumevoq (lenadogene nolparvovec, GenSight Biologics), here at the American Academy of Neurology annual meeting.
The RESTORE study included 62 of 72 patients